David A Nathanson

David A Nathanson is a Professor in the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA), School of Medicine. His research focuses on cancer metabolism, neuro-oncology, and developing therapeutic strategies for glioblastoma. He leads NIH-funded projects targeting metabolic vulnerabilities and ferroptosis mechanisms in brain tumors.

• Role: Principal Investigator on multiple NIH grants (R01NS121319, R01CA227089, etc.)
• Key Research: Glioblastoma metabolism, drug development, molecular imaging, and CAR-T cell therapies

Research interests include understanding how metabolic reprogramming and genetic alterations drive tumor progression and resistance. His work spans preclinical models to clinical translation, with a focus on combining imaging biomarkers with targeted therapies.

Publications emphasize novel drug candidates (e.g., Tegavivint), metabolic pathways (CDKN2A deletion and lipid remodeling), and imaging techniques (CEST MRI, PET tracers). Collaborations involve neurosurgeons, radiologists, and immunologists to advance precision oncology.

• Grants: Over $12M in NIH funding since 2014
• Awards: Not explicitly listed, but recognized through prestigious grant awards

Labs/Teams: Directs UCLA labs focused on glioma metabolism, CAR-T engineering, and radioligand development. Collaborates across institutions to model tumor microenvironment interactions and immune responses.